Read by QxMD icon Read

BJU International

Niranjan J Sathianathen, Yiannis A Philippou, Gretchen M Kuntz, Badrinath R Konety, Shilpa Gupta, Alastair D Lamb, Philipp Dahm
OBJECTIVES: Androgen deprivation therapy (ADT) has historically been the main management option for men with metastatic, hormone-sensitive prostate cancer. Over the last two decades, a number of agents have demonstrated a benefit in castration-resistant disease[1] and there has been interest to employ these drugs earlier in the disease course when the cancer is hormone-sensitive. Taxane-based chemotherapy has been utilized in such a manner and we aimed to assess the effects of early taxane-based chemohormonal therapy for newly diagnosed, metastatic, hormone-sensitive prostate cancer...
February 14, 2019: BJU International
Lee A Hugar, Samia H Lopa, Jonathan G Yabes, Justin A Yu, Robert M Turner, Mina M Fam, Liam C MacLeod, Benjamin J Davies, Angela B Smith, Bruce L Jacobs
OBJECTIVES: To describe the rate and determinants of palliative care use among Medicare beneficiaries with bladder cancer and encourage a national dialogue on improving coordinated urologic, oncologic, and palliative care in patients with genitourinary malignancies. MATERIALS AND METHODS: Using Surveillance, Epidemiology, and End Results-Medicare data, we identified patients diagnosed with muscle-invasive bladder cancer between 2008-2013. Our primary outcome was receipt of palliative care, defined as the presence of a claim submitted by a Hospice and Palliative Medicine subspecialist...
February 13, 2019: BJU International
Armando Stabile, Clement Orczyk, Feargus Hosking-Jervis, Francesco Giganti, Manit Arya, Richard G Hindley, Louise Dickinson, Clare Allen, Shonit Punwani, Charles Jameson, Alex Freeman, Neil McCartan, Francesco Montorsi, Alberto Briganti, Hashim U Ahmed, Mark Emberton, Caroline M Moore
OBJECTIVE: To report medium-term oncological outcomes in patients receiving primary focal treatment with HIFU for PCa. PATIENTS AND METHODS: Consecutive men treated by means of primary focal HIFU for PCa at two centres by 6 treating clinicians were assessed. Patients were submitted to either a focal ablation or hemiablation using HIFU (Sonablate 500). The primary objective of the study was to assess medium-term oncological outcomes defined as overall survival, freedom from biopsy failure, freedom from any further treatment and freedom from radical treatment after focal HIFU...
February 12, 2019: BJU International
Jorge D Mena, Medina Ndoye, Andrew J Cohen, Puneet Kamal, Benjamin N Breyer
OBJECTIVE: To evaluate the landscape of retractions of literature and determine the prevalence of research misconduct in the field of Urology. METHODS: Three databases (PUBMED, EMBASE, Retraction Watch) were queried for all retracted studies of urologic topics in both urologic and non-urologic journals from April 1999 to March 2018. Two reviewers screened the records and determined the final list of articles to be included in the analysis. RESULTS: 138 articles met the inclusion criteria...
February 12, 2019: BJU International
Samuel W D Merriel, Liz Hetherington, Andrew Seggie, Joanna T Castle, William Cross, Monique J Roobol, Vincent Gnanapragasam, Caroline M Moore
OBJECTIVES: To develop a consensus statement on current best practice of active surveillance (AS) in the UK, informed by patients and clinical experts. SUBJECTS AND METHODS: A consensus statement was drafted on the basis of three sources of data: systematic literature search of national and international guidelines; data arising from a Freedom of Information (FOI) Act request to UK urology departments regarding their current practice of AS; survey and interview responses from men with localised prostate cancer regarding their experiences and views of AS...
February 11, 2019: BJU International
Allison S Glass, Marc A Dall'Era
OBJECTIVES: To review the role of multi-parametric magnetic resonance imaging (mpMRI) for active surveillance of prostate cancer. MATERIALS AND METHODS: We performed a comprehensive search of Medline and Embase databases for relevant articles. Search terms included prostate cancer, active surveillance or monitoring, expectant management, and MRI in the English language. We also reviewed practice guidelines from recognized international associations or societies involved in prostate cancer care...
February 11, 2019: BJU International
Luke Stroman, Rajesh Nair, Beth Russell, Nabiah Malik, Arjun Desai, Ashish Chandra, Ramesh Thurairaja, Prokar Dasgupta, Muhammad Shamim Khan, Sachin Malde
OBJECTIVES: To determine if the presence of non-urothelial variant histology (NUVH) is associated with a poorer prognosis following radical cystectomy compared to pure urothelial carcinoma. PATIENTS AND METHODS: A prospectively maintained database of all patients undergoing radical cystectomy (RC) at a high-volume regional tertiary bladder cancer service between January 2010 and January 2017 was retrospectively analysed looking for patients displaying NUVH. Multivariate Cox proportional hazards regression analysis was used to determine disease recurrence, overall and bladder cancer specific survival as well as lymph node positivity...
February 11, 2019: BJU International
Mihir Desai, Mo Bidair, Kevin C Zorn, Andrew Trainer, Andrew Arther, Eugene Kramolowsky, Leo Doumanian, Dean Elterman, Ronald P Kaufman, James Lingeman, Amy Krambeck, Gregg Eure, Gopal Badlani, Mark Plante, Edward Uchio, Greg Gin, Larry Goldenberg, Ryan Paterson, Alan So, Mitch Humphreys, Claus Roehrborn, Steven Kaplan, Jay Motola, Naeem Bhojani
BACKGROUND AND AIMS: The outcomes of Aquablation in men with lower urinary tract symptoms due to benign prostatic hyperplasia (BPH) with prostate volumes between 80-150cc have not been prospectively studied. Present 6-month safety and effectiveness data from a multicenter prospective study of Aquablation. METHODS: Between September and December 2017, 101 men with BPH due to LUTS were prospectively enrolled at 16 centers from Canada and the US. RESULTS: Mean prostate volume was 107cc...
February 8, 2019: BJU International
Alexander Light, Oussama Elhage, Lorenzo Marconi, Prokar Dasgupta
Screening aims to identify prostate cancer at an early stage where curative treatment can reduce mortality. Given high false positive and false negative rates, however, the use of prostate-specific antigen (PSA) in screening has long been controversial. Recent systematic reviews comprising large randomised-controlled trials (RCTs) with long-term follow-up have demonstrated just modest benefit regarding mortality reduction compared to standard care [1,2]. Screening is also associated with overdiagnosis of clinically-insignificant tumours that never would have been diagnosed otherwise...
February 5, 2019: BJU International
J Kam, Y Yuminaga, M Krelle, D Gavin, S Koschel, K Aluwihare, T Sutherland, S Skinner, J Brennan, L M Wong, M Louie-Johnsun
OBJECTIVES: To assess the accuracy of multi-parametric MRI (mpMRI) for the detection of significant prostate cancer in men undergoing radical prostatectomy (RP) in an Australian multi-centre setting. Secondary aims were to assess concordance between mpMRI and RP for local tumour staging and index lesion locations. PATIENTS AND METHODS: Patients who had an mpMRI performed within 12 months of RP between January 2013 and August 2016 at 3 Australian Sites were included (Central Coast, NSW, St Vincents Hospital, Melbourne, VIC, and Bendigo Hospital, VIC)...
February 3, 2019: BJU International
Pavel Sluka, Carmel Pezaro, Hady Wardan, Shomik Sengupta, Ian D Davis
OBJECTIVE: To interrogate enriched prostate cancer cells and autologous non-malignant prostate epithelial cells from men with localized prostate cancer, in order to identify early oncogenic pathways. BACKGROUND: Previous work characterizing early oncogenic changes in prostate cancer, including that of the Cancer Genome Atlas, has used tissue containing cells from non-malignant components as well as from non-epithelial tissue compartments, diluting cancer-related changes...
February 3, 2019: BJU International
Alberto Abrate, Francesco Sessa, Arcangelo Sebastianelli, Mirko Preto, Alberto Olivero, Virginia Varca, Andrea Benelli, Riccardo Campi, Maurizio Sessa, Carlo Pavone, Vincenzo Serretta, Marco Vella, Eugenio Brunocilla, Sergio Serni, Carlo Trombetta, Carlo Terrone, Andrea Gregori, Andrea Lissiani, Paolo Gontero, Riccardo Schiavina, Mauro Gacci, Alchiede Simonato
OBJECTIVES: To compare overall (OS), cancer-specific (CSS), recurrence free survival (RFS) and post-operative renal function among patients affected by upper tract urothelial carcinoma (UTUC) of the distal (lower lumbar and pelvic) ureter, electively treated with segmental resection and termino-terminal anastomosis (TT) vs bladder cuff removal and ureteral re-implantation (RR). PATIENTS AND METHODS: A multicentre retrospective study, including 84 patients diagnosed with UTUC of the distal ureter and treated with TT or RR, is presented...
February 3, 2019: BJU International
Wei Shen Tan, Chin Hai Teo, Delcos Chan, Malgorzata Heinrich, Andrew Feber, Rachael Sarpong, Jennifer Allan, Norman Williams, Chris Brew-Graves, Chirk Jenn Ng, John D Kelly
OBJECTIVE: To determine the minimal accepted sensitivity (MAS) of a urine biomarker that patients are willing to accept to replace cystoscopy and to qualitatively assess their views and reasons. PATIENT AND METHODS: Patients were part of a prospective multi-center observational study recruiting patients with bladder cancer for a urine biomarker study (DETECT II; NCT02781428). A mix methods approach comprising of 1) Questionnaire to assess patients' experience with cystoscopy and patients' preference for cystoscopy vs urinary biomarker and 2)...
January 29, 2019: BJU International
Demetrios N Simopoulos, Anthony E Sisk, Alan Priester, Ely R Felker, Lorna Kwan, Merdie K Delfin, Robert E Reiter, Leonard S Marks
OBJECTIVE: To study the relationship of maximum cancer core length, on targeted biopsy of MRI-visible index lesions, to volume of that tumor found at prostatectomy. PATIENTS AND METHODS: 205 men undergoing fusion biopsy and radical prostatectomy were divided into two groups: 136 in whom the maximum cancer core length came from an index MRI-visible lesion (targeted) and 69 in whom maximum cancer core length came from a non-targeted lesion. MRI was 3T multi-parametric and biopsy was via MRI-US fusion...
January 29, 2019: BJU International
Jonathan J Aning, Gavin S Reilly, Sarah Fowler, Ben Challacombe, John S McGrath, Prasanna Sooriakumaran
OBJECTIVES: To analyse the peri-operative and oncological outcomes of all RPs performed for high risk prostate cancer(PCa) in the British Association of Urological Surgeons (BAUS) national registry from 2014-2015. PATIENTS AND METHODS: We identified and analysed outcomes of all RPs performed for high-risk PCa(clinical stage>T2 and/or biopsy Gleason Grade>7 and/or pre-operative PSA≥20) in the national registry for 2014 and 2015. Surgeon reporting of data was mandated during this period...
January 25, 2019: BJU International
Smita Pattanaik, Ravimohan S Mavuduru, Arabind Panda, Joseph L Mathew, Mayank M Agarwal, Ec Chang Hwang, Jenifer A Lyon, Shrawan K Singh, Arup K Mandal
INTRODUCTION: Lower urinary tract symptoms (LUTS) in a male patient may be due to benign prostatic hyperplasia (BPH-LUTS). In a routine clinical practice, BPH -LUTS is medically managed by Alpha-blockers (ABs) and add-on 5-alpha reductase inhibitors (5-ARIs). Epidemiological studies have shown an association of BPH-LUTS with erectile dysfunction (ED)[1]. Moreover, phosphodiesterase inhibitors (PDEIs) have shown to relieve LUTS in various studies and recently been approved by FDA for use in BPH-LUTS[2]...
January 25, 2019: BJU International
Maarten Albersen, Charlien Berghen, Pierre Blanchard, Alberto Bossi, Alberto Briganti, Cesare Cozzarini, Karel Decaestecker, Gert De Meerleer, Valérie Fonteyne, Karin Haustermans, Steven Joniau, Daryl Lim Joon, Vincent Khoo, Paul L Nguyen, Piet Ost, Geert Villeirs, Christof Vulsteke, Anthony Zietman
Germ cell tumors (GCT), accounting for 95% of malignant testicular tumors, can be divided into two groups: seminoma (SGCT) and non-seminoma (NSGCT). Seminomas typically arise in men in the fourth decade of life, compromising 60% of the GCT. At diagnosis, approximately 75% present with local disease (Stage I); 15% is detected with metastatic regional lymph nodes (Stage II) and 5-10% present with juxtaregional or visceral metastasis (Stage III) . This article is protected by copyright. All rights reserved.
January 25, 2019: BJU International
Daryl Lim Joon, Farshad Foroudi, Jason Wasiak, Michal Schneider, Michael Chao, Trish Jenkins, Vincent Khoo
The importance of a multi-disciplinary collaborative approach to urological radiation complications is highlighted in a recent study by Ma et al [1]. Their single-centre retrospective study adds to the existing body of knowledge, and the controversy in the field, regarding radiotherapy complications and toxicities from the urological perspective. The work provided some meaningful information about a subsection of patients presenting to one of the largest urology units in Australia. Furthermore, the study is well critiqued by the associated editorial that underscores many of the issues [2]...
January 23, 2019: BJU International
Alejandra Bravo-Balado, Mauricio Plata, Carlos Gustavo Trujillo, Juan Ignacio Caicedo, Adolfo Serrano, Anamaria Ramos, Juan Guillermo Cataño
It is known that the potential benefits of clinical practice guidelines (CPGs) are as good as the quality of the guidelines themselves.(1) Consequently, the use of appropriate methodologies for their elaboration processes is essential to create reliable recommendations for both physicians and patients. We aim to critically appraise the development of overactive bladder (OAB) CPGs using the AGREE II instrument. This article is protected by copyright. All rights reserved.
January 22, 2019: BJU International
Jorge D Ramos, Sarah K Holt, George R Schade, Matthew D Galsky, Jonathan L Wright, John L Gore, Evan Y Yu
BACKGROUND: Cisplatin chemotherapy is associated with increased venous thromboembolism (VTE) risk; however, other agents have been hypothesized to increase risk. OBJECTIVE: To assess the association of VTE with different chemotherapy regimens in urothelial tract cancer patients. DESIGN, SETTING, AND PARTICIPANTS: We identified patients ≥66 year-old diagnosed with urothelial tract cancer from 1998 to 2011 in the Surveillance, Epidemiology, and End Results (SEER) Medicare-linked database...
January 22, 2019: BJU International
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"